Alessandra became part of the Okairos team in 2009 and served as Director of the Respiratory Infection Vaccine Unit. She led the preclinical development of genetic vaccines for RSV and flu.
Prior to Okairos, she was a scientist at IRBM / Merck, which she joined in 1990, working first in hepatitis C infection and immunity, before becoming a group leader in Oncology. She contributed to the development of the chimpanzee adenovirus technology as a vaccine vector platform, and to the development of several monoclonal antibodies against infectious diseases and cancer.
In the past, Alessandra carried out research at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, working in the field of cell-cycle regulatory genes.
She published several articles in high-impact, peer-reviewed journals on viral infection and vaccines.
Alessandra received her degree in Biology and a PhD in Biochemistry at the University of Rome, La Sapienza.